ABEO vs. IMUX, RPTX, GLYC, CTMX, SCTL, RLMD, NVCT, CTXR, RZLT, and RNAC
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Immunic (IMUX), Repare Therapeutics (RPTX), GlycoMimetics (GLYC), CytomX Therapeutics (CTMX), Societal CDMO (SCTL), Relmada Therapeutics (RLMD), Nuvectis Pharma (NVCT), Citius Pharmaceuticals (CTXR), Rezolute (RZLT), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Abeona Therapeutics (NASDAQ:ABEO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.
80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 5.3% of Abeona Therapeutics shares are owned by insiders. Comparatively, 2.7% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Abeona Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Immunic has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500.
Abeona Therapeutics presently has a consensus target price of $36.00, indicating a potential upside of 820.72%. Immunic has a consensus target price of $8.50, indicating a potential upside of 553.85%. Given Abeona Therapeutics' higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than Immunic.
In the previous week, Abeona Therapeutics had 19 more articles in the media than Immunic. MarketBeat recorded 24 mentions for Abeona Therapeutics and 5 mentions for Immunic. Abeona Therapeutics' average media sentiment score of 0.60 beat Immunic's score of 0.16 indicating that Abeona Therapeutics is being referred to more favorably in the media.
Abeona Therapeutics has higher revenue and earnings than Immunic. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Immunic's return on equity of -157.44% beat Abeona Therapeutics' return on equity.
Abeona Therapeutics received 419 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 70.27% of users gave Abeona Therapeutics an outperform vote while only 65.73% of users gave Immunic an outperform vote.
Summary
Abeona Therapeutics beats Immunic on 10 of the 15 factors compared between the two stocks.
Get Abeona Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
